Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis
Data
2017Language
en
Soggetto
Abstract
Background and Purpose - Evidence from the real-world setting complements evidence coming from randomized controlled trials. We aimed to summarize all available evidence from high-quality real-world observational studies about efficacy and safety of nonvitamin-K oral anticoagulants compared with vitamin-K antagonists in patients with atrial fibrillation. Methods - We searched PubMed and Web of Science until January 7, 2017 for observational nationwide or health insurance databases reporting matched or adjusted results comparing nonvitamin-K oral anticoagulants versus vitamin-K antagonists in patients with atrial fibrillation. Outcomes assessed included ischemic stroke, ischemic stroke or systemic embolism, any stroke or systemic embolism, myocardial infarction, intracranial hemorrhage, major hemorrhage, gastrointestinal hemorrhage, and death. Results - In 28 included studies of dabigatran, rivaroxaban, and apixaban compared with vitamin-K antagonists, all 3 nonvitamin-K oral anticoagulants were associated with a large reduction of intracranial hemorrhage (apixaban hazard ratio [HR], 0.45; 95% confidence interval [CI], 0.31-0.63; dabigatran HR, 0.42; 95% CI, 0.37-0.49; rivaroxaban HR, 0.64; 95% CI, 0.47-0.86); similar rates of ischemic stroke and ischemic stroke or systemic embolism (apixaban HR, 1.05; 95% CI, 0.75-1.19 and HR, 1.08; 95% CI, 0.95-1.22 / dabigatran HR, 0.96; 95% CI, 0.80-1.16 and HR, 1.17; 95% CI, 0.92-1.50 / rivaroxaban HR, 0.89; 95% CI, 0.76-1.04 and HR, 0.73; 95% CI, 0.52-1.04, respectively); apixaban and dabigatran with lower mortality (HR, 0.65; 95% CI, 0.56-0.75 and HR, 0.63; 95% CI, 0.53-0.75, respectively); apixaban with fewer gastrointestinal (HR, 0.63; 95% CI, 0.42-0.95) and major hemorrhages (HR, 0.55; 95% CI, 0.48-0.63); dabigatran and rivaroxaban with more gastrointestinal hemorrhages (HR, 1.20; 95% CI, 1.06-1.36 and HR, 1.24; 95% CI, 1.08-1.41, respectively); dabigatran and rivaroxaban with similar rate of myocardial infarction (HR, 0.96; 95% CI, 0.77-1.21 and HR, 1.02; 95% CI, 0.54-1.89, respectively). Conclusions - This meta-analysis confirms the main findings of the randomized controlled trials of dabigatran, rivaroxaban, and apixaban in the real-world setting and, hence, strengthens their validity. © 2017 American Heart Association, Inc.
Collections
Related items
Showing items related by title, author, creator and subject.
-
Effect of integrin AV and B8 gene polymorphisms in patients with traumatic brain injury
Dardiotis E., Siokas V., Aloizou A.-M., Karampinis E., Brotis A.G., Grigoriadis S., Paterakis K., Dardioti M., Komnos A., Kapsalaki E., Fountas K., Hadjigeorgiou G.M. (2019)Background: Α few genetic variants are associated with the outcome after traumatic brain injury (TBI). Integrins are glycoprotein receptors that play an important role in the integrity of microvasculature of the brain. ... -
ASTRAL, DRAGON and SEDAN scores predict stroke outcome more accurately than physicians
Ntaios G., Gioulekas F., Papavasileiou V., Strbian D., Michel P. (2016)Background and purpose: ASTRAL, SEDAN and DRAGON scores are three well-validated scores for stroke outcome prediction. Whether these scores predict stroke outcome more accurately compared with physicians interested in ... -
Timing of initiation of oral anticoagulants in patients with acute ischemic stroke and atrial fibrillation comparing posterior and anterior circulation strokes
Paciaroni M., Agnelli G., Giustozzi M., Tsivgoulis G., Yaghi S., Grory B.M., Furie K.L., Tadi P., Zedde M., Abdul-Rahim A.H., Dawson J., Lees K.R., Alberti A., Venti M., Acciarresi M., D’Amore C., Mosconi M.G., Bogini V., Cappellari M., Rigatelli A., Bonetti B., Putaala J., Tomppo L., Tatlisumak T., Bandini F., Marcheselli S., Pezzini A., Poli L., Padovani A., Masotti L., Grifoni E., Vannucchi V., Sohn S.-I., Lorenzini G., Tassi R., Guideri F., Acampa M., Martini G., Ntaios G., Athanasakis G., Makaritsis K., Karagkiozi E., Vadikolias K., Liantinioti C., Palaiodimou L., Mumoli N., Porta C., Galati F., Sacco S., Tiseo C., Corea F., Ageno W., Bellesini M., Silvestrelli G., Ciccone A., Scoditti U., Denti L., Mancuso M., Caselli M.C., Maccarrone M., Ulivi L., Orlandi G., Giannini N., Tassinari T., Lodovici M.L.D., Rueckert C., Baldi A., Toni D., Gentile L., Letteri F., Giuntini M., Lotti E.M., Flomin Y., Pieroni A., Kargiotis O., Karapanayiotides T., Monaco S., Mannino M., Baronello M.M., Csiba L., Szabó L., Chiti A., Giorli E., Sette M.D., Schirinzi E., Imberti D., Zabzuni D., Doronin B., Volodina V., Michel P., Eskandari A., Vanacker P., Barlinn K., Barlinn J., Deleu D., Gourbali V., Caso V. (2020)Introduction: The aim of this study in patients with acute posterior ischaemic stroke (PS) and atrial fibrillation (AF) was to evaluate (1) the risks of recurrent ischaemic event and severe bleeding and (2) these risks in ...